Area of research
Cardiology and Cardiovascular Medicine · Endocrinology, Diabetes and Metabolism
Research interest
Research interests include Diabetes Treatment and Management, Cardiovascular Function and Risk Factors, Genetic Associations and Epidemiology, and Lung Cancer Treatments and Mutations.
Vascular Disease Burden, Outcomes and Benefits with Empagliflozin in Heart Failure: Insights From the EMPEROR-Reduced Trial
Weight Change and Clinical Outcomes in Heart Failure with Reduced Ejection Fraction: Insights from EMPEROR-Reduced
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial
Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials
Subtypes of Native American ancestry and leading causes of death: Mapuche ancestry-specific associations with gallbladder cancer risk in Chile
Using next-generation DNA sequence data for genetic association tests based on allele counts with and without consideration of zero inflation
Atlas of the clinical genetics of human dilated cardiomyopathy
Practical investigation of the performance of robust logistic regression to predict the genetic risk of hypertension
Tailored Selection of Study Individuals to be Sequenced in Order to Improve the Accuracy of Genotype Imputation
A genome-wide association study identifies 6p21 as novel risk locus for dilated cardiomyopathy
Epigenetic screen identifies genotype-specific promoter DNA methylation and oncogenic potential of CHRNB4